| Full Name | Ms Ka I Mak |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 901 Nevin Ave, Richmond, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093887523 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 43728 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Ka I Mak, 901 Nevin Ave, Richmond, CA 94801-3143 Ph: (510) 307-3173 | Ms Ka I Mak, 901 Nevin Ave, Richmond, CA 94801-3143 Ph: (510) 307-3173 |
News Archive
Smoking is the most preventable risk factor for cardiac and lung disease and is expected to cause 1 billion deaths during the 21st century. Electronic cigarettes have been marketed in recent years as a safer habit for smokers, with several millions of people already using them worldwide.
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius today issued a letter to governors and independent insurance commissioners asking each state to express their interest in participating in the temporary high-risk pool program established by the new health insurance reform law. States were provided a number of options for participation including building upon existing state high-risk pools.
Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company's MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
› Verified 5 days ago
Temitope Omotayo, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 901 Nevin Ave, Skyview Pharmacy, Richmond, CA 94801 Phone: 510-520-3985 | |
Iok I Tang, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1150 Macdonald Ave, Richmond, CA 94801 Phone: 510-236-5748 | |
Nicholas Do, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1515 | |
Jiangyan Du, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-4851 | |
Mr. Paul Pastina, PHARM D CGP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1400 Pinnacle Ct, 115, Richmond, CA 94801 Phone: 510-235-4246 | |
Mrs. Susan N Kalaei, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4500 Macdonald Ave, T1507, Richmond, CA 94805 Phone: 510-253-1001 Fax: 510-253-1011 | |
Pauline Lai-toledo, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-3161 |